白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2012年
9期
520-523
,共4页
潘飞%许莲蓉%王宏伟%朱孟霞%刘艳%覃艳红%陈秀花%张丽
潘飛%許蓮蓉%王宏偉%硃孟霞%劉豔%覃豔紅%陳秀花%張麗
반비%허련용%왕굉위%주맹하%류염%담염홍%진수화%장려
白血病,髓样,慢性%核因子-E2相关因子2%硫氧还蛋白还原酶%聚合酶链反应
白血病,髓樣,慢性%覈因子-E2相關因子2%硫氧還蛋白還原酶%聚閤酶鏈反應
백혈병,수양,만성%핵인자-E2상관인자2%류양환단백환원매%취합매련반응
Leukemia,myelogenous,chronic%Nuclear factor erythroid-2 related factor 2%Thioredoxin reductase%Polymerase chain reaction
目的 探讨慢性粒细胞白血病(CML)核因子-E2相关因子2(Nrf2)基因表达与临床特点的关系及其与硫氧还蛋白还原酶( TrxR)表达的相关性.方法 应用实时荧光定量聚合酶链反应( PCR)检测30例CML患者(慢性期20例,加速期3例,急变期7例)骨髓细胞及CML细胞株K562中Nrf2及TrxR mRNA的表达,以10例骨髓良性疾病患者骨髓细胞为正常对照.结果 CML慢性期骨髓细胞Nrf2和TrxR mRNA相对定量表达分别为5.601±1.069、9.017±2.398,加速期骨髓细胞分别为1.698±0.349、5.590±1.01 5,急变期骨髓细胞分别为1.252±0.807、5.050±1.469;正常对照组分别为1.377±0.344、1.867±0.977.CML患者Nrf2及TrxR mRNA相对表达量与正常对照组比较差异有统计学意义(x2=14.680,P=0.002；x2=8.271,P=0.041).CML加速期、急变期之间Nrf2表达量差异无统计学意义( Z=0.011,P=0.496),但与慢性期比较差异有统计学意义(Z=2.155,P=0.016;Z=2.534,P=0.006).初发与治疗组之间差异有统计学意义(Z=2.015,P=0.022).K562细胞与正常对照组间差异有统计学意义( Z=1.898,P=0.029).在CML患者骨髓细胞中Nrf2与TrxR表达呈正相关(r=0.738,P=0.037).结论 初发CML患者骨髓细胞Nrf2mRNA表达升高,经治疗后表达下降,Nrf2可作为判断病情进展的分子标志物；Nrf2与TrxR的表达有相关性.
目的 探討慢性粒細胞白血病(CML)覈因子-E2相關因子2(Nrf2)基因錶達與臨床特點的關繫及其與硫氧還蛋白還原酶( TrxR)錶達的相關性.方法 應用實時熒光定量聚閤酶鏈反應( PCR)檢測30例CML患者(慢性期20例,加速期3例,急變期7例)骨髓細胞及CML細胞株K562中Nrf2及TrxR mRNA的錶達,以10例骨髓良性疾病患者骨髓細胞為正常對照.結果 CML慢性期骨髓細胞Nrf2和TrxR mRNA相對定量錶達分彆為5.601±1.069、9.017±2.398,加速期骨髓細胞分彆為1.698±0.349、5.590±1.01 5,急變期骨髓細胞分彆為1.252±0.807、5.050±1.469;正常對照組分彆為1.377±0.344、1.867±0.977.CML患者Nrf2及TrxR mRNA相對錶達量與正常對照組比較差異有統計學意義(x2=14.680,P=0.002；x2=8.271,P=0.041).CML加速期、急變期之間Nrf2錶達量差異無統計學意義( Z=0.011,P=0.496),但與慢性期比較差異有統計學意義(Z=2.155,P=0.016;Z=2.534,P=0.006).初髮與治療組之間差異有統計學意義(Z=2.015,P=0.022).K562細胞與正常對照組間差異有統計學意義( Z=1.898,P=0.029).在CML患者骨髓細胞中Nrf2與TrxR錶達呈正相關(r=0.738,P=0.037).結論 初髮CML患者骨髓細胞Nrf2mRNA錶達升高,經治療後錶達下降,Nrf2可作為判斷病情進展的分子標誌物；Nrf2與TrxR的錶達有相關性.
목적 탐토만성립세포백혈병(CML)핵인자-E2상관인자2(Nrf2)기인표체여림상특점적관계급기여류양환단백환원매( TrxR)표체적상관성.방법 응용실시형광정량취합매련반응( PCR)검측30례CML환자(만성기20례,가속기3례,급변기7례)골수세포급CML세포주K562중Nrf2급TrxR mRNA적표체,이10례골수량성질병환자골수세포위정상대조.결과 CML만성기골수세포Nrf2화TrxR mRNA상대정량표체분별위5.601±1.069、9.017±2.398,가속기골수세포분별위1.698±0.349、5.590±1.01 5,급변기골수세포분별위1.252±0.807、5.050±1.469;정상대조조분별위1.377±0.344、1.867±0.977.CML환자Nrf2급TrxR mRNA상대표체량여정상대조조비교차이유통계학의의(x2=14.680,P=0.002；x2=8.271,P=0.041).CML가속기、급변기지간Nrf2표체량차이무통계학의의( Z=0.011,P=0.496),단여만성기비교차이유통계학의의(Z=2.155,P=0.016;Z=2.534,P=0.006).초발여치료조지간차이유통계학의의(Z=2.015,P=0.022).K562세포여정상대조조간차이유통계학의의( Z=1.898,P=0.029).재CML환자골수세포중Nrf2여TrxR표체정정상관(r=0.738,P=0.037).결론 초발CML환자골수세포Nrf2mRNA표체승고,경치료후표체하강,Nrf2가작위판단병정진전적분자표지물；Nrf2여TrxR적표체유상관성.
Objective To investigate the expression of nuclear factor erythroid-2 related factor 2 (Nrf2) gene in chronic myeloid leukemia (CML) and explore its relationship with clinical characteristics and thioredoxin reductase (TrxR).Methods The expressions of Nrf2 and TrxR genes in bone marrow cells and K562 cells were analyzed in 30 bone marrow preparations of CML patients in different phases,including 20 in chronic phase,3 in accelerated phase,7 in blastic phase by real-time quantitative polymerase chain reaction.Ten health subjects were served as normal controls.Results The relative quantitation expression of Nrf2 and TrxR mRNA were 5.601±1.069 and 9.017±2.398 in chronic phase,1.698±0.349 and 5.590±1.015 in accelerated phase,1.252±0.807 and 5.050±1.469 in blastic phase,1.377± 0.344 and 1.867±0.977 in normal controls.The expressions of both Nrf2 and TrxR mRNA in CML had significant differences from those of the normal controls (x2 =14.680,P =0.002,x2 =8.271,P =0.041).The expression of Nrf2 mRNA in accelerated phase,blastic phase group showed no significant difference (Z =0.011,P =0.496),but lower than that in chronic phase group (Z =2.155,P =0.016,Z =2.534,P =0.006).The difference between the first visit and post-treated group was significant (Z =2.015,P =0.022).The expression in K562 cells and normal controls had significant difference (Z =1.898,P =0.029).In CML patients,the expression of Nrf2 was positively correlated with that of TrxR (r =0.738,P =0.037).Conclusion The expression of Nrf2 gene is higher in the first visit group of CML than that in the other groups,and is decreased after therapy,which may be the molecular marker predicting the progress of CML.Nrf2 mRNA expression level is correlated with TrxR.
